Subscribe
shutterstock_2055997766_michael_vi
Michael Vi / Shutterstock.com
4 August 2022MedtechStaff Writer

J&J unit primed for multi-million dollar damages over counterfeits

Judge urges $18m award in ‘horrific’ counterfeiting case | Counterfeits were ‘bacterially contaminated’ | Ethicon.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
US govt bodies unite to battle fake pharma
22 December 2022   Counterfeit medicine and drugs cause more than one million deaths a year | Trio of bodies will work jointly together | National Intellectual Property Rights Coordination Center | Homeland Security Investigations.
Americas
J&J accuses ex-employees of stealing trade secrets
15 December 2022   Lawsuit alleges former employees stole a “treasure trove” of confidential information from three J&J units | Complaint says defendant engaged in a systematic process of hiring Auris staff.
Americas
J&J units launch prostate cancer drug suit
31 May 2022   Johnson & Johnson subsidiaries Aragon Pharmaceuticals and Janssen Biotech have sued three pharma companies for alleged infringement of five patents relating to prostate cancer treatment Erleada.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

More features

AIPPI: Personalised medicine tests the limits in patent law
Ropes & Gray loses 21-attorney group to join rival on growth spree
How 'Boehringer' sets preliminary relief threshold for generics
‘Whose trademark law is AI based on exactly?’: Key questions from Marques
The Quintara decision: Defining trade secrets in federal cases
To disclose or not: Pharma patents face new AI reality
Trade secrets go global: How brand owners face a high-stakes battlefront
Killing the golden goose of US drug innovation (Part II): Drug pricing myths